Navigation Links
New sickle cell anemia therapy advances to Phase II clinical trials
Date:6/12/2013

SAN DIEGO (June 12, 2013) Seeking to improve the lives of sickle cell anemia sufferers around the world, researchers from the La Jolla Institute for Allergy and Immunology, the Dana-Farber/Children's Hospital Cancer Center in Boston and the BloodCenter of Wisconsin in Milwaukee and others are preparing to launch Phase II of a clinical trial to investigate a potential new therapy for reducing the disorder's severest symptoms. Sickle cell anemia is a serious, painful and chronic illness that impedes blood flow and can lead to early death. More than 100,000 Americans and several million people worldwide suffer from this genetic disorder.

The phase II trial, funded by a $10.8 million grant from the National Institutes of Health, is testing an already existing drug called Lexiscan (regadenoson - Astellas Pharma US, Inc.), which is used for diagnosing heart disease. Researchers are exploring whether the drug's anti-inflammatory effects will significantly reduce the pain and blood flow disturbances of sickle cell anemia. A Phase I safety study was completed earlier this year. Recruitment is now under way for the trial's second phase to be conducted at treatment centers in eight major U.S. cities: Boston, Baltimore, Detroit, Chicago, Cincinnati, Milwaukee, Chapel Hill, and St. Louis.

"We are excited to begin the next phase of investigating Lexiscan's potential for reducing inflammation that contributes to the poor blood flow and serious complications of sickle cell disease," says La Jolla Institute scientist Joel Linden, Ph.D., a prominent researcher whose studies laid the groundwork for the trial. "Our phase I results were promising. Participants experienced no adverse reactions and our tests indicated that the drug significantly reduces inflammation. It is too early to tell whether this will translate into reduced pain and tissue damage. But we remain cautiously optimistic." The Phase I results were published as the cover article in th
'/>"/>

Contact: Bonnie Ward
contact@liai.org
619-303-3160
La Jolla Institute for Allergy and Immunology
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Sickle cell trait can cause sudden cardiac death in black athletes: Why is this controversial?
2. Potential gene therapy approach to sickle cell disease highlighted at ASH
3. Nature study reveals loss of essential blood cell gene leads to anemia
4. Why a hereditary anemia is caused by genetic mutation in mechanically sensitive ion channel
5. Cleveland Clinic research shows anemia drug does not improve health of anemic heart failure patients
6. Discovery may help prevent chemotherapy-induced anemia
7. Scientists identify potential drug target for treatment-resistant anemias
8. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
9. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
10. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
11. The Japanese traditional therapy, honokiol, blocks key protein in inflammatory brain damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Canada has issued a high health risk warning for ... the region due to forest fires. In the ... drifting eastward along normal wind patterns. Fire is ... from fires is not quite so obvious and its ... type of fire (forest, brush, crop, structure, tires, waste ...
(Date:7/23/2014)... DC -- The planet,s soil releases about 60 billion ... is far more than that released by burning fossil ... This enormous release of carbon is balanced by carbon ... other plant matter, as well as by the underground ... have documented that rising temperatures increase the rate of ...
(Date:7/23/2014)... local and national governments struggle to deal with ever-growing ... refining the picture of just how much there is ... ACS journal Environmental Science & Technology , their ... developed countries discard floods into just seven developing countries ... who live there. , Knut Breivik and colleagues note ...
Breaking Biology News(10 mins):Climate change and the soil 2
... State University have solved a long-standing conundrum about ... way into limestone, sand grains, mussel shells, coral ... According to the lead investigator, ASU professor ... what is "at the heart of an erosive ...
... sugar may be enough to cool a hot temper, at least ... found that people who drank a glass of lemonade sweetened with ... than did people who consumed lemonade with a sugar substitute. ... simple sugar found in the bloodstream that provides energy for the ...
... 30, 2010Access to quality reproductive healthcare for women around ... human rights, freedom, equity, and right to control her ... Health in the current issue of Journal of Women,s ... Inc., explores the compelling medical, socioeconomic, and gender-based factors ...
Cached Biology News:Mystery dissolves with calcium pump discovery 2Mystery dissolves with calcium pump discovery 3Researchers find link between sugar, diabetes and aggression 2Researchers find link between sugar, diabetes and aggression 3Researchers find link between sugar, diabetes and aggression 4Ensuring the rights of women worldwide to reproductive health care 2
(Date:7/23/2014)... Vienna University of Technology and the Maria Curie-Skłodowska ... semiconductor crystals into a silicon nanowire. With this ... and multi-functional processing units can be accommodated on ... results will be published in the journal ... cornerstone of future chip technology, but the research ...
(Date:7/23/2014)... 2014 Shimadzu Scientific Instruments has ... analysis system developed jointly with Ajinomoto Co. Inc. ... analyze 38 amino acids in nine minutes, drastically ... high-speed analysis utilizing a fast application-specific column and ... analytical results even under conditions with difficult samples ...
(Date:7/23/2014)... 23 de julio de 2014 ADB ... Compañía) ha anunciado hoy una asociación con Austen ... (ABIA o el Instituto), para el propósito de ... de terapia de señal bioeléctrica (el E-QURE BST ... Instituto, que tiene una importante experiencia en cicatrización ...
(Date:7/23/2014)... DuPont Pioneer announced today that Neal Gutterson, ... Agricultural Biotechnology (ABT), effective July 21, 2014. Gutterson joins ... as president, chief executive officer and board member. , ... seed and crop protection industry to this integral role ... president of DuPont Pioneer. “I am looking forward to ...
Breaking Biology Technology:A crystal wedding in the nanocosmos 2Shimadzu's New UF-Amino Station Provides High-Speed, Multi-Component Analysis of Amino Acids in Food & Beverage and Pharmaceutical Testing 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3
... 24 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), ... it will hold a conference call to discuss,the ... update,including an update on the clinical development plan ... Ph.D., chairman and chief,executive officer, Ronald A. Martell, ...
... Ill., July 24 Sagent Pharmaceuticals, Inc.,a privately-held ... ceftazidime for injection, USP, a semisynthetic,broad-spectrum, beta-lactam antibiotic. ... dose vials and 6g pharmacy bulk package vials. ... in the United States were,approximately $45.7 million., ...
... Company reports double-digit sales and earnings growth, ... LLY ) today announced financial results for ... presented on a reported basis. Reported,results were prepared ... include all sales and expenses recognized by the,company ...
Cached Biology Technology:Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31 2Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP 2Lilly Reports Solid Second-Quarter Results 2Lilly Reports Solid Second-Quarter Results 3Lilly Reports Solid Second-Quarter Results 4Lilly Reports Solid Second-Quarter Results 5Lilly Reports Solid Second-Quarter Results 6Lilly Reports Solid Second-Quarter Results 7Lilly Reports Solid Second-Quarter Results 8Lilly Reports Solid Second-Quarter Results 9Lilly Reports Solid Second-Quarter Results 10Lilly Reports Solid Second-Quarter Results 11Lilly Reports Solid Second-Quarter Results 12Lilly Reports Solid Second-Quarter Results 13Lilly Reports Solid Second-Quarter Results 14Lilly Reports Solid Second-Quarter Results 15Lilly Reports Solid Second-Quarter Results 16Lilly Reports Solid Second-Quarter Results 17Lilly Reports Solid Second-Quarter Results 18Lilly Reports Solid Second-Quarter Results 19Lilly Reports Solid Second-Quarter Results 20Lilly Reports Solid Second-Quarter Results 21
... Enhancing signals in immunostaining ,This solution has ... allows to get clearer signal than the ... reduce the amount of secondary antibody used ... accordingly you can have images with high ...
Anti-human VEGFR-2/KDR (Protein-A Purified) Polyclonal Antibody...
... exists predominantly as XDH which converts hypoxanthine ... plasma antioxidant. During ischemia, XDH is ... XO by oxidation of essential sulfhydryl groups ... the amino-terminus. AO has a higher ...
Anti-TNKS2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
Biology Products: